Low HR and thus good prognosis was associated with enhanced GPCR methylation (spot B’) in NL (M6), IDH-O (M5), and also in M4 tumors, which enrich lower-grade II IDH-A gliomas. The gene discussed is IDH1; the disease is central nervous system cancer.